

Research

Open Access

Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study

Pilar Carrasco Garrido¹, Javier de Miguel Díez², Javier Rejas Gutiérrez*³, Antonio Martín Centeno⁴, Elena Gobartt Vázquez⁵, Ángel Gil de Miguel¹, Marta García Carballo¹ and Rodrigo Jiménez García¹

Address: ¹Preventive Medicine and Public Health Department, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain, ²Department of Pneumology, University Hospital Gregorio Marañón, Madrid, Spain, ³Department of Health Outcomes Research, Medical Unit, Pfizer España, Parque Empresarial La Moraleja, Avda de Europa, 20-B, 28108 Alcobendas, Madrid, Spain, ⁴Respiratory Area, Medical Unit, Pfizer España, Alcobendas, Madrid, Spain and ⁵Medical Department, Boehringer Ingelheim SA, Sant Cugat del Vallés, Barcelona, Spain

Email: Pilar Carrasco Garrido - pilar.carrasco@urjc.es; Javier de Miguel Díez - Jmiguel.hgugm@salud.madrid.org; Javier Rejas Gutiérrez* - javier.rejas@pfizer.com; Antonio Martín Centeno - antonio.martin@pfizer.com; Elena Gobartt Vázquez - elena.gobartt@bcn.boehringer-ingelheim.com; Ángel Gil de Miguel - angel.gil@urjc.es; Marta García Carballo - marta.garcia@urjc.es; Rodrigo Jiménez García - rodrigo.jimenez@urjc.es

* Corresponding author

Published: 23 May 2006

Received: 09 March 2006

Health and Quality of Life Outcomes 2006, 4:31 doi:10.1186/1477-7525-4-31

Accepted: 23 May 2006

This article is available from: <http://www.hqlo.com/content/4/1/31>

© 2006 Garrido et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: COPD is currently the fourth cause of morbidity and mortality in the developed world. Patients with COPD experience a progressive deterioration and disability, which lead to a worsening in their health-related quality of life (HRQoL). The aim of this work is to assess the Health-Related Quality of Life (HRQoL) of patients with stable COPD followed in primary care and to identify possible predictors of disease.

Methods: It is a multicenter, epidemiological, observational, descriptive study. Subjects of both sexes, older than 40 years and diagnosed of COPD at least 12 months before starting the study were included. Sociodemographic data, severity of disease, comorbidity, and use of health resources in the previous 12 months were collected. All patients were administered a generic quality-of-life questionnaire, the SF-12, that enables to calculate two scores, the physical (PCS-12) and the mental (MCS-12) component summary scores.

Results: 10,711 patients were evaluated (75.6% men, 24.4% women), with a mean age of 67.1 years (SD 9.66). The mean value of FEV₁ was 35.9 ± 10.0%. Mean PCS-12 and MCS-12 scores were 36.0 ± 9.9 and 48.3 ± 10.9, respectively. Compared to the reference population, patients with COPD had a reduction of PCS-12, even in mild stages of the disease. The correlation with FEV₁ was higher for PCS-12 (r = 0.38) than for MCS-12 (r = 0.12). Predictors for both HRQoL components were sex, FEV₁, use of oxygen therapy, and number of visits to emergency rooms and hospital admissions. Other independent predictors of PCS-12 were age, body mass index and educational level.

Conclusion: Patients with stable COPD show a reduction of their HRQoL, even in mild stages of the disease. The factors determining the HRQoL include sex, FEV₁, use of oxygen therapy, and number of visits to emergency rooms and hospital admissions.

Background

Chronic obstructive pulmonary disease (COPD) is characterized by the presence of a limitation to airflow that is not completely reversible and is associated with an abnormal inflammatory response to gases or inhaled toxic particles, mainly tobacco [1,2]. COPD is currently the fourth cause of morbidity and mortality in the developed world [1]. The IBERPOC study, carried out in 7 different geographical areas with nearly 5000 patients, has shown that in Spain the prevalence of COPD in the general population aged between 40 and 69 years is 9.1%, and is a first-order public health problem [3]. This condition originates approximately 10–12% of primary care consultations and 35–40% of those of pneumology, and causes 35% of definitive occupational disabilities and 7% of hospital admissions [4].

As the condition progresses, patients with COPD experience a progressive deterioration and disability, which lead to a worsening in their health-related quality of life (HRQoL). However, it has been confirmed that the evaluation alone of the severity of COPD, measured by the degree of reduction of the forced expiratory volume in one second (FEV_1), does not provide sufficient information to establish the health condition perceived by the patients. The interest for HRQoL measurement in patients with COPD has grown in recent years. The fact that HRQoL is the result of the interaction of multiple physical, psychological and social factors, unique for each individual, can justify this interest from the scientific community [5]. Each of these domains can be measured with the objective of establishing the performance or health condition and the subjective perception of health. The HRQoL can be quantified through various health evaluation questionnaires, both general and specific, widely validated [6]. The former covers a broad range of dimensions, enable the comparison between groups of patients with different diseases, and facilitate the detection of problems or unexpected effects [7]. One of them is the Short Form 36 (SF-36) questionnaire [8], that has an abbreviated version (SF-12) [9,10]. Since one of the main objectives of the treatment of COPD is to improve the general health condition [1], it is important to identify possible factors determining the HRQoL of these patients. Some of these have been identified previously [11]. Relationships have been shown between HRQoL during acute exacerbation of chronic bronchitis with post-exacerbation functional status, hospital readmission for acute exacerbation or COPD and mortality [12-16].

The objective of this study was to assess the HRQoL of a group of patients with stable COPD followed in primary care and to identify the associated determinant factors.

Methods

Design and population of the study

This study is part of the EPIDEPOC study, a multicenter, epidemiological, observational, descriptive project, carried out in the primary care setting, with the aim of estimating the use of health resources and assessing the HRQoL of patients with stable COPD.

The recruitment of patients and the calculation of sample size correspond to that performed in the EPIDEPOC study. For the calculation of sample size, a cluster design was used, considering 3 types of variables: health centers, physicians, and medical records. Finally, it was estimated that it was necessary to include 2422 physicians, each of whom should recruit 5 patients. The screening of patients was performed at random by primary care physicians from all Spanish Autonomous Communities, whose distribution was weighed based on the population distribution of the different Autonomous Communities over the total national. The patients were recruited during a period of three months (from 1st January to 31st March 2003).

Subjects of both sexes, aged 40 years or older and diagnosed of COPD at least 12 months before the start of the study, were included. The diagnosis of the disease was performed according to the criteria of the Spanish Society of Pneumology and Chest Surgery (SEPAR) based on the demonstration, through a forced spirometry, of a forced expiratory volume in 1 second (FEV_1) below 80% of the reference value and a FEV_1 /forced vital capacity (FVC) ratio below 0.7 after the bronchodilation test. The severity of the disease was rated at three levels according to the FEV_1 value: mild (FEV_1 60–80% of the reference value), moderate (FEV_1 40–59% of the reference value) and severe (FEV_1 below 40% of the reference value), in accordance with the SEPAR criteria [17].

Individuals suffering at the time of the study a neurological or psychiatric disease precluding measurement were excluded. Patients with an acute worsening of their COPD in the previous month were also excluded. An acute worsening was considered to be the occurrence of an impairment of the clinical condition of the patient characterized by an increased baseline dyspnea, purulent sputum, increased volume of sputum or any combination of these symptoms, of acute onset, and requiring a change in the regular medication of the patient [18].

The study was approved by the Ethics Committee of the Foundation Hospital Alcorcón, and all patients gave their oral consent to participate in it. All the information obtained will be considered as confidential and disclosed and kept following the regular safety standards (Organic Act 15/1999, of 13 December on the Protection of personal data).

Table 1: Sociodemographic and clinical characteristics of patients

Characteristic (no. of patients)	
Total no. of patients	10,711
Age (years) * (8665)	64.1 ± 9.7 (40; 98)
Age groups (8862)	
40–54 years	963 (10.9)
55–64 years	2,249 (25.4)
65–74 years	3,669 (41.4)
>75 years	1,981 (22.4)
Sex (man) (10620)	8,030 (75.6)
Residence population (10341)	
<10,000 inhabitants	3,022 (29.2)
10,000–100,000	3,449 (33.4)
>100,000	3,870 (37.4)
Educational level (9018)	
No studies	1,852 (20.5)
Primary	5,111 (56.7)
Secondary	1,582 (17.5)
University	473 (5.2)
Smoking (10649)	
Never	2,468 (23.2)
Ex-smoker	6,153 (57.8)
Active smoker	2,028 (19.0)
FEV₁ (9963)	35.9 ± 10.0 (4;80)
COPD Severity (9963)	
Mild	3,634 (35.5)
Moderate	5,471 (53.4)
Severe	1,146 (11.2)
Visits to E.R. * (9505)	1.4 ± 1.9 (0; 12)
No. of hospital admissions * (8670)	0.5 ± 0.9 (0; 11)
Oxygen therapy (10007)	1351 (13.5)
Associated comorbidity	
Hypertension (9876)	4,706 (47.7)
Hypercholesterolemia	3,995 (41.3)
Diabetes (9453)	1,598 (16.9)
Heart disease (9390)	1,770 (18.8)
Ulcer (9425)	1,637 (17.4)
Depression (9333)	1,196 (12.8)
Anxiety (9397)	2,084 (19.5)

Value expressed as frequencies (percentages)

* Value expressed as mean ± standard deviation (minimum; maximum).

Assessment of the patients

A single visit was completed, collecting in all cases the sociodemographic data, severity of the disease, comorbidity, and utilization of health resources in the previous 12 months. All patients were administered the SF-12 quality of life questionnaire, an abbreviated version of the SF-36 health questionnaire that contains 12 items [9]. These 12 items explain more than 90% of the variance of the physical and mental component scores of the SF-36. From them two scores can be calculated, the physical (PCS-12) and the mental (MCS-12) component summary, using a value of 50 with a standard deviation of 10 as reference population. In this study, the general Spanish adult population has been used as reference [19]. The SF-12 is

scored from 0 to 100 so that, the higher the score, the better the health condition.

Statistical analysis

The analysis of the data was carried out through the statistical package SPSS 11.0 for Windows. The qualitative variables were described as frequency and percentage and the quantitative variables as mean, standard deviation, minimum and maximum. To analyze the relationship between the qualitative variables the χ^2 Pearson test was used. ANCOVA and ANOVA models with sex, age and disease severity as covariates were applied for between group comparisons. Bonferroni adjustment was applied for multiple comparisons. To evaluate the correlation among the values of the quantitative data, the Pearson's correlation coefficient was used. Finally, a multiple regression analysis was performed using as dependent variable the physical or mental component of the HRQoL and as independent variables: age, sex, smoking, size of the habitat, educational level, body mass index, FEV₁, treatment with oxygen therapy, visits to emergency rooms and hospital admissions. Independent variables included in the model were chosen from those showing significance differences in the bivariate analysis or deemed to be potential confounders. A value of $p < 0.05$ was considered to be significant.

Results

The number of physicians participating in the study was 2,377, which enabled to recruit a total of 10,711 patients (75.6% men, 24.4% women), with a mean age of 67.1 years (SD 9.66), and a mean body mass index of 27.6 (4.0) kg/m². Table 1 shows the sociodemographic and clinical characteristics of the sample studied. The mean FEV₁ value was 35.9 ± 10.0%. The severity of the disease was mild in 35.5% of the cases, moderate in 53.4%, and severe in 11.2%. The concomitant conditions most frequently detected were hypertension (47.7%), hypercholesterolemia (41.3%), anxiety (22.2%), heart disease (18.8%), gastroduodenal ulcer (17.4%), diabetes (16.9%), and depression (12.8%). With regard to the use of health resources in the previous year, the mean values were: visits to primary care physician 6.66 (SD 5.71), visits to pneumologist 1.43 (SD 1.52), visits to emergency rooms 1.60 (SD 2.71), and hospital admissions 0.50 (SD 1.17).

The mean PCS-12 and MCS-12 scores were 36.0 ± 9.9 and 48.3 ± 10.9, respectively. As compared to the reference population, patients with COPD had a reduction of PCS-12, regardless of sex, age range or degree of airflow obstruction. However, a significant decrease was only seen in MCS-12, vs the reference population, in women and patients with severe COPD, with no differences in this parameter related to age (Figure 1). Figure 2 shows the




Figure I
Relationship of quality of life to sex, age, and severity of COPD.




Figure 2
Relationship between quality of life, sex, and degree of airflow obstruction.

relationship between quality of life, sex, and degree of airflow obstruction. With regard to the PCS-12, significant differences were only detected between men and women in patients with moderate COPD. With regard to MCS-12, differences were found between the two sexes in patients with mild and moderate COPD, but not in patients with severe COPD.

The use of oxygen therapy was associated with a significant reduction of the quality of life, in both PCS-12 and MCS-12. Table 2 shows the distribution of the mean scores of both parameters based on the use of oxygen therapy and the variables related to utilization of health resources.

PCS-12 was correlated positively to FEV₁ (r = 0.38, p < 0,001), however the correlation with the mental component (MCS-12) was lower (r = 0.12). Tables 3 and 4 show the factors determining physical and mental components of the HRQoL, respectively. The determinant factors of MCS-12 were sex, FEV₁, use of oxygen therapy, and number of visits to emergency rooms and hospital admissions. The PCS-12 was also determined by age, Body Mass Index and educational level. Smoking was not significantly related to any of the components of HRQoL.

Discussion

This study shows that patients with stable COPD have, as compared to the reference population, a reduction of PCS-12, even in the initial stages, though they only show a reduction in MCS-12 in the most advanced phases of the disease. The determinant factors of both components of HRQoL include sex, FEV₁, use of oxygen therapy and

number of visits to emergency rooms and hospital admissions. In addition, the age, educational level and body mass index are also variables that influence the PCS-12.

The women in our study had lower HRQoL levels than men, both in the physical and mental component of quality of life. Several authors have reported that women usually suffer more respiratory symptoms than men [20], which could partly justify this finding. Furthermore, it has been demonstrated that, after adjusting for smoking, women show a higher risk of hospital admission for COPD than men [21].

Most previous studies have detected a mild to moderate association between the different areas of HRQoL and the degree of airflow obstruction [22-28]. In our study, a higher correlation has been found with the physical vs the mental component of HRQoL. Thus, it seems that the effects of COPD on health are not only mediated by the severity of the airflow limitation. For instance, it has been shown that the health condition perceived by the patients correlates better with the degree of dyspnea [29,30] or with the distance walked in the walking test [31] than with FEV₁. The patients who obtain better results in these parameters report a limitation to fulfill their activities and the disease has less impact in their daily life.

The influence of hypoxemia and oxygen therapy on the HRQoL of patients with COPD has been assessed in previous studies. Some of them have found no relationship between HRQoL and the presence of respiratory failure [32,33]. On the contrary, we have observed that the use of oxygen therapy is a predictive factor independent from the

Table 2: Physical (PCS-12) and mental (MCS-12) component summaries related to the use of oxygen therapy and the utilization of health resources in the past year

	No. of cases	PCS-12	MCS-12
Oxygen therapy:			
No	3,131 (84.8%)	32.4 (31.3; 33.5)	45.8 (44.4; 47.2)
Yes	562 (15.2%)	30.3 (29.1; 31.6)	43.7 (42.1; 45.3)
P		0.019	0.049
No of visits to primary care:			
1 to 5	1,941 (52.3%)	32.9 (31.3; 34.5)	46.4 (44.3; 48.4)
5 to 10	1,140 (30.9%)	31.0 (29.5; 32.4)	44.2 (42.3; 46.0)
Over 10	612 (16.6%)	31.0 (29.7; 32.3)	44.6 (42.9; 46.2)
P		0.130	0.241
No. of visits to pneumology:			
None	883 (23.9%)	32.8 (30.9; 34.8)	48.7 (46.2; 51.1)
1 to 4	2,711 (73.4%)	31.1 (30.3; 32.0)	44.7 (43.6; 45.8)
Over 4	99 (2.7%)	31.0 (28.9; 33.1)	41.6 (38.9; 44.2)
P		0.277	0.000
No. of visits to E.R.:			
None	1,481 (40.1%)	34.8 (32.7; 36.9)	48.2 (45.5; 50.8)
1 to 2	1,508 (40.8%)	31.5 (30.0; 33.1)	45.6 (43.6; 47.6)
3 to 4	466 (12.6%)	30.2 (28.8; 31.7)	45.0 (43.2; 46.8)
Over 4	238 (6.4%)	30.9 (29.2; 32.7)	41.8 (39.6; 44.0)
P		0.004	0.003
No. of hospital admissions:			
None	2,544 (68.9%)	33.7 (32.5; 35.0)	47.4 (45.8; 49.0)
1	755 (20.4%)	32.1 (30.5; 33.7)	43.1 (41.1; 45.1)
2	257 (7.0%)	29.2 (27.4; 31.1)	44.3 (42.1; 46.6)
Over 2	137 (3.7%)	29.5 (27.2; 31.7)	43.8 (41.0; 46.6)
P		0.000	0.006

Variables expressed as mean (95% CI).

health condition perceived by the patients. Similar results have been obtained in other studies. Thus, Okubadejo et al. [34] demonstrated, through a multivariate model, the existence of a relationship between HRQoL and the severity of hypoxemia. More recently, Ferreira et al. [35] have also demonstrated a marked worsening of HRQoL in patients with COPD receiving long-term oxygen therapy, with greater influence on physical and social function dimensions. Several reasons have been proposed to justify the trend of the patients to reject the treatment with oxygen therapy. These include the negative expectation linked to the use of an apparatus for long time periods to maintain health, the noise caused by the device, the mobility restriction resulting of its use, and the limitation involved by the fact that the patient must be confined at home most of the time [33,36,37].

Acute worsening is a common adverse event in the natural history of patients with COPD. It is the most common reason for medical visits, hospital admissions, and death in these patients [38]. Furthermore, there is an increasing evidence of the impact of these events on the health condition of patients with COPD. Thus, it has shown that patients suffering more than three annual acute worsening of COPD had a significantly greater impairment in

their quality of life than those with a lower number of acute worsening [39,40]. Furthermore, Fan et al. [41] have shown that HRQoL is a predictive factor independent from hospitalization and mortality in these patients. In our study it has been also detected that the visits to emergency rooms and hospital admissions for acute worsening of the disease in the last year influence significantly the quality of life of patients with COPD, affecting both the physical and mental component.

The influence of age on HRQoL in patients with COPD is controversial. Some studies have detected no association between the two parameters [42] and others have demonstrated it through a logistic regression analysis that is an independent factor [23,43]. In our study we have only found a relationship with the physical component of quality of life, but not with the mental. The same has happened with other parameters such as the educational level of the patients evaluated. It is possible that subjects with a higher educational level have a greater purchasing power and have more material resources and, on the contrary, those with a lower level belong to the most disadvantaged classes, complaining later of health problems, have a higher environmental exposure, and the percentage of smokers among them is higher [43].

Table 3: Coefficients of the multiple linear regression equation for the final physical component of quality of life

Independent variables	Coefficients (95% CI)		Standard coefficients	Sig.
Constant	48.6	(44.8; 52.3)		<0.001
Age	-0.25	(-0.28; -0.27)	-0.233	<0.001
Sex	-1.21	(-1.91; -0.51)	-0.050	0.001
Educational level	1.22	(0.82; 1.62)	0.092	<0.001
FEV₁	0.019	(0.16; 0.26)	0.226	<0.001
Oxygen therapy	-2.84	(-3.75; -1.93)	-0.101	<0.001
Body Mass Index	-0.17	(-0.24; -0.10)	-0.068	<0.001
≤ 2 visits to E.R.	-0.84	(-1.02; -0.66)	-0.162	<0.001
≤ 2 hospital admissions	-0.93	(-1.31; -0.54)	-0.086	<0.001

R² = 0.31

Dependent variable: final physical component.

Variables excluded: size of the habitat, smoking

There is no agreement on the relationship between BMI and HRQoL. There seems to be an association between a poor nutritional status and quality of life worsening in patients with COPD, particularly those with emphysema [44]. Our results confirm that there is an association, though it is only demonstrated with the mental component of quality of life. The same has happened in another recent study, which only found a relationship with emotional function, though it was weak [43]. On the contrary, other authors have not evidenced any influence of body-weight on the HRQoL of the patients with COPD [29,45].

Some limitations may have influenced the results of this study. First, we have used a generic questionnaire to measure HRQoL, less sensitive than the specific tools. However, the large sample size of our study enables to compensate this effect and give validity to our model. Second, all the patients were from primary care, so the results may not be extrapolable to all patients with COPD. However, a recent study evaluating this has found no relationship between HRQoL and the healthcare level [29].

In conclusion, the HRQoL of the patients with COPD is in part related to some parameters, including sex, airflow limitation, use of oxygen therapy and number of acute

worsening and hospital admissions. However, these factors do not predict overall the high variability of HRQoL. Despite this, their measurement enables to identify the patients with a greater disability and enhances the assessment of the effects of various interventions on a standard basis.

Competing interests

Javier Rejas Gutierrez and Antonio Martin Centeno are employees at Pfizer Spain and Elena Gobartt Vázquez is employee at Boehringer Ingelheim SA. The other authors have not any conflict of interest with Pfizer or Boehringer Ingelheim SA. This study has been funded by an unrestricted grant from Pfizer Spain and Boehringer Ingelheim SA.

Authors' contributions

PCG, JRG, MGC, AGM and RJG have made substantive intellectual contributions to conception and design, acquisition of data and analysis and interpretation of data. PCG, JRG, JMD, AGM, and EGV have been involved in drafting the manuscript and revising it critically for important intellectual content. All authors have given final approval of the version to be published.

Table 4: Coefficients of the multiple linear regression equation for the final mental component of quality of life

Independent variables	Coefficients (95% CI)		Standard coefficients	Sig.
Constant	52.6	(50.5; 54.8)		<0.001
Sex	-5.71	(-6.57; -4.84)	-0.21	<0.001
FEV₁	0.08	(0.04; 0.11)	0.09	<0.001
Oxygen therapy	-2.25	(-3.38; -1.13)	-0.07	<0.001
≤ 2 visits to E.R.	-0.63	(-0.86; -0.40)	-0.11	<0.001
≤ 2 hospital admissions	-1.01	(-1.49; -0.53)	-0.09	<0.001

R² = 0.11

Dependent variable: final mental component.

Variables excluded: size of the habitat, age, smoking, educational level, Body Mass Index.

Acknowledgements

To all patients and primary care physicians who have voluntarily collaborated in the EPIDEPOC study. This study has been financed by Pfizer S.A. and Boehringer Ingelheim SA through contract No. A040 signed with the University Rey Juan Carlos of Madrid.

References

- Pauwels RA, Buist AS, Calverley PMA, Jenkins ChR, Hurd SS, on behalf of the GOLD Scientific Committee: **Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary.** *Am J Respir Crit Care Med* 2001, **163**:1256-1276.
- Celli BR, MacNee W, committee members: **Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.** *Eur Respir J* 2004, **23**:932-946.
- Sobradillo Peña V, Miravittles M, Gabriel R, Jimenez-Ruiz CA, Villante C, Masa JF, Viejo JL, Fernández Fau L: **Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study.** *Chest* 2000, **118**:981-989.
- Álvarez Sala JL, Cimas E, Masa JF, Miravittles M, Molina J, Naberán K, Simonet P, Viejo JL: **Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica.** *Arch Bronconeumol* 2001, **37**:269-278.
- Jones PW: **Health status measurement in chronic obstructive pulmonary disease.** *Thorax* 2001, **56**:880-887.
- Mahler D: **How should health-related quality of life be assessed in patients with COPD?** *Chest* 2000, **117**:54S-57S.
- Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D: **Quality of life measures in health care. II: Design, analysis, and interpretation.** *BMJ* 1992, **305**:1145-1148.
- Ware JE, Sherbourne CD: **The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.** *Med Care* 1992, **30**:473-483.
- Ware JE, Kosinski M, Keller SD: **A 12-item short-form health survey. Construction of scales and preliminary tests of reliability and validity.** *Med Care* 1996, **34**:220-233.
- Gandek B, Ware J, Aaronson N, Apolone G, Bjorner J, Brazier J, Bullinger M, Kaasa S, Leplege A, Prieto L, Sullivan M: **Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: result from the IQUOLA project.** *J Clin Epidemiol* 1998, **51**:1171-1178.
- Doll H, Miravittles M: **Health-Related QOL in Acute Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease. A review of the Literature.** *Pharmacoeconomics* 2005, **23**(4):345-363.
- Almagro P, Calbo E, de Echagüen AO, et al.: **Mortality after hospitalisation for COPD.** *Chest* 2002, **121**:1441-8.
- Connors AF, Dawson NV, Thomas C, et al.: **Outcomes following acute exacerbation of chronic obstructive pulmonary disease.** *Am J Respir Crit Care Med* 1996, **154**:959-67.
- García-Aymerich J, Farrero E, Félez MA, et al.: **Risk factors of re-admission to hospital for a COPD exacerbation a prospective study.** *Thorax* 2003, **58**:100-5.
- Lynn J, Ely W, Zhong Z, et al.: **Living and dying with chronic pulmonary obstructive disease.** *J Am Geriatr Soc* 2000, **48**:S91-S100.
- Osman LM, Godden DJ, Friend JAR, et al.: **Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease.** *Thorax* 1997, **52**:67-71.
- Barberà JA, Peces-Barba G, Agustí AGN, Izquierdo JL, Monsó E, Montemayor T, Viejo JL, Sociedad Española de Neumología y Cirugía Torácica (SEPAR): **Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica.** *Arch Bronconeumol* 2001, **37**:297-316.
- Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: **Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.** *Ann Intern Med* 1987, **106**:196-204.
- Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, Santed R, Valderas JM, Ribera A, Domingo-Salvany A, Alonso J por los investigadores de la Red-IRYSS: **El cuestionario de salud SF-36 español: una década de experiencia y nuevos desarrollos.** *Gaceta Sanitaria* in press.
- Langhammer A, Johnsen R, Holmen J, Gulsvik A, Bjermer L: **Cigarette smoking gives more respiratory symptoms among women than among men. The Nord-Trøndelag Health Study (HUNT).** *J Epidemiol Community Health* 2000, **54**:917-922.
- Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J: **Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a danish longitudinal population study.** *Eur Respir J* 1997, **10**:822-827.
- Ketekaars CAJ, Schlösser MAG, Mostert R, Huyer Abu-Saad H, Hal-fens RJG, Wouters EFM: **Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease.** *Thorax* 1996, **51**:39-43.
- Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, Plaza V, Prieto L, Anto JM: **Chronic obstructive pulmonary disease stage and health-related quality of life.** *Ann Intern Med* 1997, **127**:1072-1079.
- Tsukino M, Nishimura K, Ikeda A, Koyama H, Mishima M, Izumi T: **Physiologic factors that determine the health-related quality of life in patients with COPD.** *Chest* 1996, **110**:896-903.
- Engström CP, Persson LO, Larsson S, Ryden A, Sullivan M: **Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking. A descriptive and comparative study.** *Thorax* 1996, **51**:825-830.
- Miravittles M, Alvarez-Sala JL, Lamarca R, Ferrer M, Masa F, Vereá H, Zalacain R, Murio C, Ros F, IMPAC Study Group: **Treatment and quality of life in patients with chronic obstructive pulmonary disease.** *Qual Life Res* 2002, **11**:329-338.
- Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: **Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.** *BMJ* 2000, **320**:1297-1303.
- Spencer S, Calverley PM, Sherwood Burge P, Jones PW: **Health status deterioration in patients with chronic obstructive pulmonary disease.** *Am J Respir Crit Care Med* 2001, **163**:122-128.
- De Miguel Díez J, Izquierdo Alonso JL, Rodríguez González-Moro JM, de Lucas Ramos P, Bellón Cano JM, Molina Paris J: **Calidad de vida en la enfermedad pulmonar obstructiva crónica. Influencia del nivel de asistencia de los pacientes.** *Arch Bronconeumol* 2004, **40**:431-437.
- Mahler DA, Tomlinson D, Olmstead EM, Tosteson AN, O'Connor GT: **Changes in dyspnea, health status, and lung function in chronic airway disease.** *Am J Respir Crit Care Med* 1995, **151**:61-65.
- Jones PW, Quirk FH, Baveystock CM, Littlejohns P: **A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire.** *Am Rev Respir Dis* 1992, **145**:1321-1327.
- Prigatano GP, Wright EC, Levin D: **Quality of life and its predictors in patients with chronic obstructive pulmonary disease.** *Arch Intern Med* 1984, **144**:1613-1619.
- McSweeney J, Grant I, Heaton RK, Adams KM, Timms RM: **Life quality of patients with chronic obstructive pulmonary disease.** *Arch Intern Med* 1982, **142**:473-478.
- Okubadejo AA, Jones PW, Wedzicha JA: **Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia.** *Thorax* 1996, **51**:44-47.
- Ferreira CAS, Stelmach R, Feltrin MIZ, Filho WJ, Chiba T, Cukier A: **Evaluation of health-related quality of life in low-income patients with COPD receiving long-term oxygen therapy.** *Chest* 2003, **123**:136-141.
- Wedzicha JA: **Effects of long-term oxygen therapy on neuropsychiatric function and quality of life.** *Respir Care* 2000, **45**:119-124.
- Okubadejo AA, O'Shea L, Jones PW, Wedzicha JA: **Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long-term oxygen therapy.** *Eur Respir J* 1997, **10**:1572-1575.
- Burrows B, Earle RH: **Course and prognosis of chronic obstructive lung disease: a prospective study of 200 patients.** *N Engl J Med* 1969, **280**:397-404.
- Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries D, Wedzicha JA: **Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.** *Am J Respir Crit Care Med* 1998, **157**:1418-1422.
- Miravittles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Vereá H, Murio C, Ros F, Vidal R, IMPAC Study Group: **Effect of**

exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. *Thorax* 2004, **59**:387-395.

41. Fan VS, Curtis JR, Tu S, McDonell MB, Fihn SD: **Using quality of life to predict hospitalization and mortality in patients with obstructive lung disease.** *Chest* 2002, **122**:429-436.
42. Ketekaars CAJ, Schlösser MAG, Mostert R, Huyer Abu-Saad H, Halfens RJG, Wouters EFM: **Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease.** *Thorax* 1996, **51**:39-43.
43. De la Iglesia Martínez F, de la Fuente Cid R, Ramos Polledo V, Pellicer Vázquez C, Nicolás Miguel R, Diz-Lois Martínez F: **Análisis factorial de la calidad de vida relacionada con la salud de pacientes con enfermedad pulmonar obstructiva crónica estable.** *Arch Bronconeumol* 2001, **37**:410-416.
44. Yohannes AM, Roomi J, Waters K, Connolly MJ: **Quality of life in elderly patients with COPD: measurement and predictive factors.** *Respir Med* 1998, **92**:1231-1236.
45. Tsukino M, Nishimura K, Ikeda A, Koyama H, Mishima M, Izumi T: **Physiologic factors that determine the health-related quality of life in patients with COPD.** *Chest* 1996, **110**:896-903.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

